Division of H. Lundbeck AS
Latest From Lundbeck Inc.
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.
Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.
Dainippon drug likely to become first atypical to be approved for adolescent schizophrenia in Japan following planned filing based on positive new Phase III results.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Ovation Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- H. Lundbeck AS
- Senior Management
- Doug Carlson, Sr. Dir., Corp. BD & Strategy
- Contact Info
Phone: (800) 455-1141
4 Parkway N.
Deerfield, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.